Nautilus Biotechnology, Inc. NAUT · Stock Open Nautilus Biotechnology, Inc. in new tab
Nautilus Biotechnology, Inc. Analysis (NAUT)
Is Nautilus Biotechnology, Inc. a good investment? Nautilus Biotechnology, Inc. (NAUT) is currently trading at 1.01 USD.
Earnings Schedule: Nautilus Biotechnology, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -0.74.
Investor FAQ
Does Nautilus Biotechnology, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Nautilus Biotechnology, Inc.?
Nautilus Biotechnology, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -0.46.
Company Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Community Discussion